Vasohibin 1, a clinically relevant biomarker, contributes to pre-eclampsia

Area of Science:

• Biochemistry
• Reproductive Biology
• Pathophysiology

Background:

• Pre-eclampsia is a major cause of maternal mortality, characterized by hypertension and proteinuria.
• Current understanding of pre-eclampsia mechanisms is limited, and effective therapies are lacking.
• There is a critical need for reliable biomarkers for early diagnosis and management of pre-eclampsia.

Purpose of the Study:

• To investigate the potential of Vasohibin-1 (VASH1) as a diagnostic biomarker for pre-eclampsia.
• To evaluate the correlation between VASH1 levels and pre-eclampsia status.
• To explore the role of VASH1 in angiogenesis and its regulation under hypoxic conditions.

Main Methods:

• VASH1 levels were quantified using ELISA and immunoblotting in serum and placental tissues from pre-eclamptic and healthy pregnant women.
• Cellular assays assessed the impact of VASH1 on cell migration and invasion.
• Quantitative PCR (qPCR) determined VASH1 expression under varying oxygen concentrations.

Main Results:

• VASH1 expression was significantly higher in the serum and placenta of pre-eclampsia patients.
• Increased VASH1 levels impaired cell migration and invasion and reduced matrix metalloproteinase (MMP) 2 and 9 expression.
• Hypoxia induced VASH1 in trophoblast cells and placental explants via a hypoxia-inducible factor 1-alpha (HIF-1α)-dependent pathway.

Conclusions:

• VASH1 is a potential novel biomarker for pre-eclampsia.
• VASH1 levels may correlate positively with the severity of pre-eclampsia.
• VASH1's role in angiogenesis under hypoxia warrants further investigation for therapeutic strategies.